Report
Rune Majlund Dahl
EUR 85.90 For Business Accounts Only

Demant (Buy, TP: DKK240.00) - Focus on 2023 guidance

We believe focus with the H2 results will be on the 2023 guidance; we expect Demant to guide for organic growth of 1–5% YOY (we forecast 4.1%, consensus 3.6%) and EBIT of DKK3,400m–3,700m (we forecast DKK3,611m, consensus DKK3,558m). We expect continued weak markets in 2023 but see less pressure on costs from freight rates. We reiterate our BUY but have cut our target price to DKK240 (260).
Underlying
Demant A/S

William Demant Holding is a holding company. Through its subsidiaries, Co develops, manufactures and sells products and equipment designed to aid the hearing and communication of individuals. Co. focuses on four areas: Hearing Devices, Diagnostic Instruments, Hearing Implants and Personal Communication. Co.'s hearing devices include Oticon, Bernafon, Sonic, Phonic Ear, and FrontRow. Co.'s Hearing implant consist of Oticon Medical. Co.'s diagnostic instruments include Maico, Interacoustics, Amplivox, Grason-Stadler, MedRx, and Micromedical. Co.'s personal communication consists of Sennheiser Communications.

Provider
DnB Markets
DnB Markets

DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.

 

Analysts
Rune Majlund Dahl

ResearchPool Subscriptions

Get the most out of your insights

Get in touch